To be published in the Proceedings of the International Radiation Protection Association 8th Congress, to be held in Montreal, Canada, May 1992. COMPARISON OF THE EFFECTS OF INHALED ²³⁹PuO₂ AND β -EMITTING RADIONUCLIDES ON THE INCIDENCE OF LUNG CARCINOMAS IN LABORATORY ANIMALS

F.F. Hahn, W.C. Griffith, B.B. Boecker,
B.A. Muggenburg and D.L. LundgrenCONF-920501--8Inhalation Toxicology Research Institute
P.O. Box 5890DE92 004259Albuquerque, New Mexico 87185, U.S.A.DE92 004259

ABSTRACT: The health effects of inhaling radioactive particles when the lung is the primary organ irradiated were studied in rats and dogs. The animals were exposed to aerosols of 239 PuO₂ or fission-product radionuclides in insoluble forms and observed for their life span. Lung carcinomas were the primary late-occuring effect. The incidence rate for lung carcinomas was modeled using a proportional hazard rate model. Linear functions predominated below 5 Gy to the lung. The life-time risk for lung carcinomas per 10⁴ Gy for beta emitters was 60 for rats and 65 for dogs, and for 239 PuO₂ it was 1500 for rats and 2300 for dogs.

INTRODUCTION: Irradiation of the lung in sufficiently high doses is known to result in lung carcinomas. This result has been demonstrated in populations of patients with ankylosing spondylosis treated with thoracic irradiation, in survivors of atomic bomb explosions in Japan, and underground miners exposed to radon and radon daughter products. None of these situations, however, directly applies to chronic alpha or beta irradiation of the deep, or alveolar, portions of the lung. Such can occur if individuals inhale radioactive particles such as might be released in reactor accidents or waste transportion accidents. No human populations are available for study that have inhaled particles of alpha- or beta-emitting radionuclides which deposit deep in the lung. To address this situation, studies were initiated at the Inhalation Toxicology Research Institute to establish the dose-response relationships resulting from the inhalation of plutonium dioxide or beta-emitting radionuclides with different radioactive halflives. This paper briefly summarizes the dose-response for lung carcinomas induced by these types of lung irradiation.

METHODS: Details of the experimental design, animal exposure, dosimetry, and husbandry techniques have been reported. ¹⁻³ Beagle dogs were exposed briefly, per nasum, to aerosols of ²³⁹PuO₂ of different monodisperse particle size or ⁹⁰Y, ⁹¹Y, ¹⁴⁴Ce or ⁹⁰Sr in relatively insoluble forms. F344 rats were similarly exposed but only to ²³⁹PuO₂ or ¹⁴⁴CeO₂. The animals were observed for their life spans for resulting biologic effects. At present, all animals have died, except for some of the dogs exposed to ²³⁹PuO₂. The incidence rate for lung carcinomas was modeled as the observed time course for the appearance of carcinomas using a proportional hazard rate model. The proportional hazards calculation of relative and absolute risks was made using the following relationships:

Proportional hazards: $\lambda(t) = \lambda_0(t)(1 + \beta D(t))$.

In this relationship, $\lambda(t)$ is the age-specific lung tumor incidence rate at dose D(t), $\lambda_0(t)$ is the background lung tumor incidence rate, β is the relative risk coefficient, and D(t) is the

DISTOBUTION COLORS DOCUMENT IS UNLIMITED

AC 14- 76-L V "MASTER

time-dependent, cumulative absorbed dose to the lung. The relative and lifetime absolute risks are:

Relative risk per Gy = β Lifetime risk per Gy = $\frac{1}{D(t)} \int_0^t S(\tau) (\lambda(\tau) - \lambda_0(\tau) d\tau)$,

where $S(\tau)$ is the fractional survival at time τ . This method is similar to the techniques used in the BEIR IV and BEIR V models of risk analysis.

RESULTS: The biological effects of these expsoures have been documented elsewhere. ³⁻⁶ Briefly, at the highest doses, animals died within months to 3 years with pulmonary injury. Those living longer (rats >1 yr, dogs >2 yr) developed a high incidence of lung tumors. <u>Table 1</u> gives the total number of lung tumors seen, the relative distribution of tumor types for each species and the types of radiation.

TABLE 1

LUNG TUMOR TYPE	RATS		DOGS	
	α-emitters	β-emitters	α-emitters	β-emitters
(# of Tumors)	(172)	(24)	(108)	(110)
Adenoma	9	13	1	2
Adenocarcinoma	70	62	96	59
Squamous Cell Carcinoma	19	21	1	9
Hemangiosarcoma	1	4	0	25
Other Sarcomas	1	0	2	5

Distribution (%) of Lung Tumor Types in Animals that Inhaled Radionuclides and Were Observed for Life Span

The predominant tumor types were adenocarcinomas and squamous cell carcinomas for rats and for dogs, adenocarcinomas and hemangiosarcomas. The hemangiosarcomas and other sarcomas are unusual tumors and occured at higher doses. The dose-response analyses are based on the carcinoma incidences.

For dogs, the relative risk was estimated by summing a linear function of dose and a power function of dose. The power function applies to the higher doses and the linear function of dose predominates over the power function at doses below 5 Gy for beta irradiation and 0.5 Gy for alpha irradiation (Fig. 1).




FIGURE 1 - Risk factors for lung carcinomas in dogs and rats that inhaled ²³⁹PuO₂ or beta-emitting radionuclides.

These analysis show a reasonable agreement between the life-time risks for lung carcinomas for rats and dogs for both alpha- and beta-emitting radionuclides.

Lifetime risks of lung carcinomas were calculated by integrating, over the life-time, the sum of the estimated lung carcinoma incidence rate at 1 Gy from the proportional hazard rate model and the mortality rate for competing causes of death in the control animals. The dose of 1 Gy was used because it did not cause an increase in competing causes of death. The lifetime risks of lung carcinomas per 10^4 Gy for beta-emitting radionuclides were 60 for rats and 65 for dogs. For ²³⁹PuO₂ the lifetime risk was 1520 for rats and 2300 for dogs. The ratio of ²³⁹PuO₂ risk to beta-emitter risk is 25 for rats and 36 for dogs. Although those ratios are higher than the presently accepted quality factor of 20 for alpha and x-irradiation, the uncertainties in this analysis would not exclude a value of 20. On the other hand, the results may indicate that the quality factor of 20 is too low for comparing radiation-induced lung carcinoma incidence of alpha irradiation with that of beta irradiation.

ACKNOWLEDGEMENTS: Research supported by the U.S. DOE/OHER under Contract No. DE-AC04-76EV01013 in facilities fully accredited by the American Association for the Accreditation of Laboratory Animal Care.

REFERENCES

- McClellan, R.O., Boecker, B.B., Hahn, F.F. and Muggenburg, B.A., 1986. Lovelace ITRI Studies on the Toxicity of Inhaled Radionuclides in Beagle Dogs, pp. 74-96 in Life-Span Radiation Effects in Animals: What can they tell us? Eds. Thompson, R.C. and Mahaffey, J.A., Office of Scientific and Technical Information, U.S., D.O.E., CONF - 830951
- 2. Lundgren, D.L., Hahn, F.F., Diel, J.H. and Snipes, M.B., 1991. Repeated Inhalation Exposure of Rats to Aerosols of ¹⁴⁴CeO₂ I. Dosimetry. *Radiation Research* (Submitted).
- Lundgren, D.L., Haley, P.J., Hahn, F.F., Diel, J.H., Griffith, W.C. and Scott, B.R., 1991. Pulmonary Carcinogenecity of Repeated Inhalation Exposure of Rats to Aerosols of ²³⁹PuO₂. *Radiation Research* (Submitted).
- 4. Lundgren, D.L., Hahn, F.F., Diel, J.H., 1991. Repeated Inhalation Exposure of Rats to Aerosols of ¹⁴⁴CeO₂ II Biological Effects. *Radiation Research* (Submitted).
- 5. Hahn, F.F. and Lundgren, D.L., 1991. Morphologic Characteristics of Lung Tumors in Rats That Inhaled ¹⁴⁴CeO₂. *Toxicologic Pathology* (Submitted).
- 6. Annual Report on Long-Term Dose-Response Studies of Inhaled or Injected Radionuclides, Oct. 1, 1989 through Sept. 30, 1990 (1991). Eds. Boecker, B.B., Muggenburg, B.A., Miller, S.C. and Bradley, P.L., National Technical Information Service, U.S. DOE, LMF-130.

DISCLAIMER

This report was prepared as an account of work sponsored by an agency of the United States Government. Neither the United States Government nor any agency thereof, nor any of their employees, makes any warranty, express or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or any agency thereof. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States Government or any agency thereof.